Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of GFH375 combined with cetuximab or chemotherapy in KRAS G12D-mutant advanced solid tumors
CTR20253996Phase 2Active
- Sponsor
- GenFleet Therapeutics
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH375 in Nonhematologic neoplasms, sponsored by GenFleet Therapeutics. Started Oct 2025; status: active.
02
Drugs
GFH375
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20253996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253996.